Alexander E Felice

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7188505/publications.pdf

Version: 2024-02-01

62 papers	1,930 citations	331670 21 h-index	254184 43 g-index
62 all docs	62 docs citations	62 times ranked	2455 citing authors

#	Article	IF	Citations
1	Haploinsufficiency for the erythroid transcription factor KLF1 causes hereditary persistence of fetal hemoglobin. Nature Genetics, 2010, 42, 801-805.	21.4	323
2	Environmental risk factors for Parkinson's disease and parkinsonism: the Geoparkinson study. Occupational and Environmental Medicine, 2007, 64, 666-672.	2.8	228
3	Systematic documentation and analysis of human genetic variation in hemoglobinopathies using the microattribution approach. Nature Genetics, 2011, 43, 295-301.	21.4	142
4	Sepiapterin reductase deficiency: A Treatable Mimic of Cerebral Palsy. Annals of Neurology, 2012, 71, 520-530.	5.3	125
5	Sepiapterin reductase deficiency: a congenital dopa-responsive motor and cognitive disorder. Brain, 2005, 128, 2291-2296.	7.6	112
6	Gene-environment interactions in parkinsonism and Parkinson's disease: the Geoparkinson study. Occupational and Environmental Medicine, 2007, 64, 673-680.	2.8	93
7	Erythroid phenotypes associated with KLF1 mutations. Haematologica, 2011, 96, 635-638.	3.5	78
8	The EuroBioBank Network: 10 years of hands-on experience of collaborative, transnational biobanking for rare diseases. European Journal of Human Genetics, 2015, 23, 1116-1123.	2.8	63
9	Population Structure in the Mediterranean Basin: A Y Chromosome Perspective. Annals of Human Genetics, 2006, 70, 207-225.	0.8	56
10	Different ? globin gene deletions among Black Americans. Human Genetics, 1986, 73, 221-224.	3.8	42
11	Mutation screening of the muscarinic M2 and M3 receptor genes in normal and asthmatic subjects. British Journal of Pharmacology, 2001, 133, 43-48.	5.4	37
12	KLF10 gene expression is associated with high fetal hemoglobin levels and with response to hydroxyurea treatment in Î²-hemoglobinopathy patients. Pharmacogenomics, 2012, 13, 1487-1500.	1.3	37
13	(AÎ³Î²)Â°-Thalassaemia in Blacks is due to a deletion of 34 kbp of DNA. British Journal of Haematology, 1985, 59, 343-356.	2.5	36
14	Anomaly in the Î³ chain heterogeneity of the newborn. Nature, 1977, 265, 63-65.	27.8	35
15	Novel Polymorphisms Influencing Transcription of the Human CHRM2 Gene in Airway Smooth Muscle. American Journal of Respiratory Cell and Molecular Biology, 2004, 30, 678-686.	2.9	35
16	The association of sickle cell anemia with heterozygous and homozygous Î±-thalassemia-2: In vitro HB chain synthesis. American Journal of Hematology, 1979, 6, 91-106.	4.1	31
17	Organization of ?-chain genes among Hb G-Philadelphia heterozygotes in association with Hb S, ?-thalassemia, and ?-thalassemia-2. Biochemical Genetics, 1982, 20, 689-701.	1.7	31
18	Recommendations for genetic variation data capture in developing countries to ensure a comprehensive worldwide data collection. Human Mutation, 2011, 32, 2-9.	2.5	25

#	Article	IF	Citations
19	Genomic variation in the MAP3K5 gene is associated with Î²-thalassemia disease severity and hydroxyurea treatment efficacy. Pharmacogenomics, 2013, 14, 469-483.	1.3	25
20	Molecular genetics of tetrahydrobiopterin (BH4) deficiency in the Maltese population. Molecular Genetics and Metabolism, 2007, 90, 277-283.	1.1	24
21	Hb Evans or Î±₂62(E11)Valâ†'MetÎ²₂; an Unstable Hemoglobin Causing a Mild Hemolytic Anemia. Hemoglobin, 1989, 13, 557-566.	0.8	23
22	An Electronic Infrastructure for Research and Treatment of the Thalassemias and Other Hemoglobinopathies: The Euro-Mediterranean Ithanet Project. Hemoglobin, 2009, 33, 163-176.	0.8	23
23	Effects of Î±-thalassemia-2 on the developmental changes of hematological values in children with sickle cell disease from georgia. American Journal of Hematology, 1987, 25, 389-400.	4.1	22
24	Identification and quantitation of embryonic and three types of fetal hemoglobin produced on induction of the human pluripotent leukemia cell line K-562 with hemin. American Journal of Hematology, 1982, 12, 1-12.	4.1	21
25	The Î²+IVS, I-NT no. 6 (Tâ†'C) thalassaemia in heterozygotes with an associated Hb Valletta or Hb S heterozygosity in homozygotes from Malta. British Journal of Haematology, 1993, 83, 669-671.	2.5	20
26	Treatment of leg ulcers with platelet-derived wound healing factor (pdwhfs) in a patient with beta thalassaemia intermedia. British Journal of Haematology, 2001, 112, 527-529.	2.5	17
27	The linkage of Hb Valletta [?2?287(F3)Thr?Pro] and Hb F-Malta-I [?2 G?2117(G19)His?Arg] in the Maltese population. Human Genetics, 1991, 86, 591-4.	3.8	16
28	Hb S, Hb G-PHILADELPHIA AND Î±-THALASSEMIA-2 IN A BLACK FAMILY. Pediatric Research, 1980, 14, 266-267.	2.3	14
29	Alternate Organization of Î± G-Philadelphia Globin Genes Among U.S. Black and Italian Caucasian Heterozygotes. Hemoglobin, 1984, 8, 537-547.	0.8	14
30	GYNOCARE Update: Modern Strategies to Improve Diagnosis and Treatment of Rare Gynecologic Tumorsâ€"Current Challenges and Future Directions. Cancers, 2021, 13, 493.	3.7	14
31	ÎÎ²-Thalassemia in a Mexican Family: Clinical Differences Among Homozygotes. Hemoglobin, 1978, 2, 513-529.	0.8	12
32	Detection and quantitation of the fetal hemoglobin variant Hb F-Malta-I in adults. Biochemical Genetics, 1977, 15, 915-923.	1.7	11
33	Is the trimodality of Hb leslie (Î±2Î²2131Gln â†' 0) in heterozygotes the result of a variable number of active Î±-chain genes? Evidence for posttranslational control of hemoglobin synthesis. American Journal of Hematology, 1978, 5, 1-9.	4.1	11
34	Case Report: Identification of an HNF1B p.Arg527Gln mutation in a Maltese patient with atypical early onset diabetes and diabetic nephropathy. BMC Endocrine Disorders, 2018, 18, 28.	2.2	11
35	Hb Nottingham (Î±;2Î²;2 (FG5) 98 VALâ†'GLY) in a Caucasian Male: Clinical and Biosynthetic Studies. Hemoglobin, 1978, 2, 315-332.	0.8	10
36	Genetic causes of Parkinsonâ€™s disease in the Maltese: a study of selected mutations in LRRK2, MTHFR, QDPR and SPR. BMC Medical Genetics, 2016, 17, 65.	2.1	10

#	Article	IF	Citations
37	In vitro synthesis of hemoglobin and hemoglobin chains in the BFUe-derived colonies from persons with Î±- or Î²-thalassemia. American Journal of Hematology, 1981, 10, 227-237.	4.1	9
38	?-Thalassemia and the production of different ? chain variants in heterozygotes. Biochemical Genetics, 1981, 19, 487-498.	1.7	9
39	Clinical and Hematological Evaluation of two Î´⁰Î´⁰- Thalassemia Homozygotes. Hemoglobin, 1981, 5, 153-164.	0.8	9
40	Adult and Fetal Hemoglobin Production in Erythroid Colonies from Subjects with Î²-Thalassemia or with Hereditary Persistence of Fetal Hemoglobin (HPFH). Hemoglobin, 1980, 4, 449-467.	0.8	8
41	The Occurrence and Identification ofÎ±-Thalassemia-2 among Hemoglobin S Heterozygotes. American Journal of Clinical Pathology, 1981, 76, 70-73.	0.7	8
42	Observations on the Calculated Contents of Variant and Normal Î± Chains in Adult and Fetal Erythrocytes. Hemoglobin, 1979, 3, 475-480.	0.8	7
43	Characterization and locus assignment of two Î±-globin variants present in the maltese population: Hb St. Luke's [Î±95(G2)Proâ†'Arg] and Hb Setif [Î±94(G1)Aspâ†'Tyr]. Hemoglobin, 1999, 23, 145-157.	0.8	6
44	Interaction of the Î² chain variant hemoglobin leslie and the Î± chain variant hemoglobin montgomery in a black female. American Journal of Hematology, 1980, 8, 139-147.	4.1	5
45	HB Setif [Î±94(GI)ASPÃTYR] in Malta. Hemoglobin, 1997, 21, 91-96.	0.8	5
46	ComparativeIn VivoExpression of Î²+-Thalassemia Alleles. Hemoglobin, 1999, 23, 221-229.	0.8	5
47	Genetic factors in risk assessment for the development of type 2 diabetes mellitus in a small case series. International Journal of Risk and Safety in Medicine, 2011, 23, 119-123.	0.6	5
48	Identification of an HNF1A p.Gly292fs Frameshift Mutation Presenting as Diabetes During Pregnancy in a Maltese Family. Clinical Medicine Insights: Case Reports, 2019, 12, 117954761983103.	0.7	5
49	Epigenomic analysis of KLF1 haploinsufficiency in primary human erythroblasts. Scientific Reports, 2022, 12, 336.	3.3	5
50	Two new missense mutations (P134T and A244V) in the coagulation factor VII gene. Human Mutation, 1998, 11, S189-S191.	2.5	4
51	Developmental Effect of theXmnI Site onGÎ³-Globin Gene Expression Among Newborn Hb F-Malta-I [GÎ³117(G19)Hisâ†'Arg, CATâ†'CGT] Heterozygotes and Adult Î²+-Thalassemia Homozygotes. Hemoglobin, 2007, 31, 71-82.	0.8	4
52	A Review ofCis-TransInterplay Between DNA Sequences 5â€² to theGÎ³- and Î²-Globin Genes Among Hb F-Malta-I Heterozygotes/Homozygotes and Î²-Thalassemia Homozygotes/Compound Heterozygotes, and the Effects of Hydroxyurea on the Hb F/F-Erythrocyte; the Need for Large Multicenter Trials. Hemoglobin, 2007, 31, 279-288.	0.8	4
53	KLF1 Dependent Pathways In Developmental Globin Gene Switching. Blood, 2010, 116, 5162-5162.	1.4	2
54	Hb Valletta [Î²87(F3)Thrâ†'Pro] and Hb Marseille/Long Island [Î²2(NA2)Hisâ†'Pro; (â€"1)Met-(+1)Val-(+2)Pro-Leu], in a Unique Compound Heterozygote with a Normal Hemoglobin Phenotype. Hemoglobin, 2010, 34, 169-174.	0.8	1

#	Article	IF	Citations
55	Immunoglobulin G in Platelet-Derived Wound Healing Factors. BioMed Research International, 2021, 2021, 1-16.	1.9	1
56	Does Quantitative Heterogeneity of Human Fetal Hemoglobin (Hb F) Reveal Friends or Foes of KLF1 in Globin Gene Switching ?. Blood, 2011, 118, 1092-1092.	1.4	1
57	Polymerase chain Reaction in molecular biotechnology; appropriate technology for developing countries. World Journal of Microbiology and Biotechnology, 1996, 12, 467-471.	3.6	0
58	international journal for hemoglobin research. Hemoglobin, 2003, 27, 137-137.	0.8	0
59	A Twenty-Five Year Prospective Clinical Review and Family Studies Revealed New Globin Gene Regulators for Hb F Induction. Hemoglobin, 2019, 43, 337-337.	0.8	0
60	Guardianship by Peer Review in Genetic Engineering and Biotechnology. Philosophy and Medicine, 1998, , 117-129.	0.3	0
61	A Functional Single Nucleotide Polymorphism in the AÎ³ Globin Gene Promoter Affects Globin Chain Synthesis. Blood, 2020, 136, 20-20.	1.4	0
62	Genetic Heterogeneity of KLF1, a Master Regulator of Erythropoiesis, Revealed an Autosomal Recessive Î²-Thalassemia and a Very Strong Promoter In Vivo. Blood, 2020, 136, 7-7.	1.4	0